Erschienen in:
18.03.2020 | ASO Author Reflections
ASO Author Reflections: Fibrolamellar Hepatocellular Carcinoma and Alpha-Fetoprotein
verfasst von:
James D. McDonald, MD, Jonathan M. Hernandez, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 6/2020
Einloggen, um Zugang zu erhalten
Excerpt
Fibrolamellar hepatocellular carcinoma (FLC) is a rare liver tumor that classically arises in the background of a noncirrhotic liver, affects younger patients, and rarely shows an elevation in AFP. Although first described in 1956, it was identified 25 years later as a variant of hepatocellular carcinoma (HCC).
1,
2 From the time it was first described, the major tenants of care have changed little. Surgical resection is the mainstay, because these tumors are poorly responsive to chemotherapy. The majority of our clinical knowledge of FLC comes from small, single-institution series, with associated ambiguity in the datasets.
3 …